EUVIMEDEUVIMED entdecken
Open Access

Semi-Synthesis of Dimeric Cannabidiol Derivatives and Evaluation of their Affinity at Neurological Targets

Zachary Stryker iD, Jorge I Castillo-Arellano iD, Stephen J Cutler, Michael D Wyatt iD, Francisco León iD

Journal of Natural Products · 2025

DOI: 10.1021/acs.jnatprod.4c01174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Natural Products, 2025. Verfasst von Zachary Stryker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina 29208, United State…. Hauptthemen laut MEDLINE: Cannabidiol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabidiol (CBD) is a natural product associated with a wide range of biological and therapeutic activities. Despite the widespread cultural acceptance of CBD as a medicinal agent, much remains to be determined regarding its precise mechanism(s) of action in treating multiple conditions. CBD has been shown to promiscuously interact with several neurological targets with varying affinities. To expand the chemical space of phytocannabinoids and develop novel chemical compounds, we have designed and synthesized a series of CBD and Δ8-THC homodimers, and CBD/Δ8-THC heterodimers. The capacity of the dimers to interact with a panel of CNS targets was explored along with the capacity to activate CB1 receptors, as measured by a GIRK channel activation assay. In the panel screen, the dimers were shown to be generally more active toward 5-HT2B and sigma 2 receptors with a range of Ki values from 0.6 to 8.7 μM. These findings provide early evidence that this new class of dimers can serve as novel chemical entities to explore receptor function and the potential for these dimers to have bivalent, bitopic, or dual mechanisms of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolMolecular StructureHumansReceptor, Cannabinoid, CB1DronabinolDimerization

Substanzen

CannabidiolReceptor, Cannabinoid, CB1Dronabinol

Autor:innen und Institutionen

  • Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina 29208, United States.

ORCID-Profile: Zachary Stryker, Jorge I Castillo-Arellano, Michael D Wyatt, Francisco León

Förderung

  • NIH HHS
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Stryker, Z., Castillo-Arellano, J. I., Cutler, S. J., Wyatt, M. D., & León, F. (2025). Semi-Synthesis of Dimeric Cannabidiol Derivatives and Evaluation of their Affinity at Neurological Targets. Journal of Natural Products. https://doi.org/10.1021/acs.jnatprod.4c01174

Vancouver

Stryker Z, Castillo-Arellano JI, Cutler SJ, Wyatt MD, León F. Semi-Synthesis of Dimeric Cannabidiol Derivatives and Evaluation of their Affinity at Neurological Targets. Journal of Natural Products. 2025. doi:10.1021/acs.jnatprod.4c01174

BibTeX
@article{Stryker2025,
  author = {Stryker, Zachary and Castillo-Arellano, Jorge I and Cutler, Stephen J and Wyatt, Michael D and León, Francisco},
  title = {Semi-Synthesis of Dimeric Cannabidiol Derivatives and Evaluation of their Affinity at Neurological Targets},
  journal = {Journal of Natural Products},
  year = {2025},
  doi = {10.1021/acs.jnatprod.4c01174}
}
Kostenlos starten →